Surya Singh, MD, Vice President, Medical Benefit Management, CVS Caremark, says the buy-and-bill model is most typically applied to the provider space, and more specifically to physicians' offices. It describes the supply chain for infusion medications, predominately self-injectables that require clinical monitoring, and that are administered or sourced through practitioners. In this model, buying refers to the procurement of the drugs by the practice, and the billing refers to the bill sent directly to payers. "There's been a growth in the number of hospital outpatient centers that source drugs and then bill payers directly through their contracts," says Dr Singh; "And that's on the rise given the acquisitions of physician practices in oncology and in other relevant specialties."
Views: 2214 AJMCtv
Patient, Elizabeth Acuna, describes some of the medications she has been on, and currently is taking, to treat her atopic dermatitis, and their effect on her quality of life.
Views: 3638 AJMCtv
In this segment, Zachary Bloomgarden, MD; Robert Gabbay, MD, PhD, FACP; Silvio Inzucchi, MD; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, discuss sodium-glucose co-transporter 2 inhibition in patients with diabetes and corresponding outcomes on cardiovascular events.
Views: 1683 AJMCtv
There is an ongoing debate about how aggressively to lower low-density lipoprotein (LDL) cholesterol, but Steve Nissen, MD, of Cleveland Clinic, argues that studies have shown an aggressive approach to lowering LDL always shows benefits.
Views: 1690 AJMCtv
Nat Turner, co-founder and CEO of Flatiron Health, says that clinical research accessibility is one of the biggest barriers in oncology care that Flatiron Health is working to remove.
Views: 860 AJMCtv
The new ADHD drug for adults, Mydayis, works with multiple beads being released at different times of the day so patients are only taking one medication that lasts for up to 16 hours instead of multiple dosings throughout the day, explained Manisha Madhoo, MD, vice president of Global Medical Affairs, Neuroscience, Shire.
Views: 3001 AJMCtv
John B. Buse, MD, PhD, offers his perspective on the LEADER trial with liraglutide and the potential reasons for the cardiovascular effects in patients with type 2 diabetes.
Views: 634 AJMCtv
During the opening segment of this program, part of the Healthcare Reform Stakeholders Summit, Spring 2015 series, moderator Dennis Patrick Scanlon, PhD, asks managed care stakeholders Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, for their insights on the goals of value-based purchasing programs and the roles of various stakeholders in these programs.
Views: 2434 AJMCtv
Tina Joseph, PharmD, BCACP, assistant professor, college of pharmacy, Nova Southeastern University, discusses collaborative practice agreements between pharmacists and physicians as well as the challenges with and best practices for successful implementation.
Views: 380 AJMCtv
Expert John Anderson, MD, reviews the cardiovascular outcomes data available to date with GLP-1 receptor agonists in type 2 diabetes.
Views: 557 AJMCtv
The accountable care organization (ACO) programs—the Pioneer, Shared Savings, and Next Generation models—and how they relate to provider risk is addressed by panel members Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, during this 12th session of the Healthcare Reform Stakeholder Summit. Risk factors for various models are also discussed.
Views: 1972 AJMCtv
Liz Zhou, MD, director of evidence-based medicine at Sanofi Medical Affairs outlined the purpose of a study on real-world results of comparing basal insulin dose changes in type 2 diabetes patients using Lantus who either stay on Lantus or switch to Toujeo.
Views: 590 AJMCtv
Dennis P. Scanlon, PhD; Zachary T. Bloomgarden, MD, MACE; Robert Gabbay, MD, PhD, FACP; Michael Gardner, MD; and John A. Johnson, MD, MBA; discuss the results of recent clinical trials that evaluated cardiovascular outcomes associated with various diabetes treatments when used as add-on therapy.
Views: 2396 AJMCtv
Zachary T. Bloomgarden, MD, MACE, describes the treatment options available for the management of diabetes and remarks on the differences between the clinical guidelines that have been released to assist healthcare providers in managing patients with diabetes.
Views: 1439 AJMCtv
At this year’s ECTRIMS conference in Boston, Alasdair Coles, MD, University of Cambridge, discussed alemtuzumab and its effectiveness in treating multiple sclerosis (MS). Dr Coles presented data from a four-year study, with MS patients being given alemtuzumab infusions during the first year. Results revealed that on average, patients showed less severity in their disability than that recorded at baseline with a low relapse rate and low risk of acquiring new disability. In addition, Dr Coles noted that alemtuzumab caused far less shrinkage of brain volume in patients with MS than that caused by beta interferon treatment. Dr Coles is confident that this news will reassure doctors, patients, and regulatory agencies when considering alemtuzumab for treatment of patients with MS. “We can say to patients now, ‘If you take alemtuzumab, it will prevent tissue loss that otherwise would have occurred.’”
Views: 710 AJMCtv
Rick Doubleday, the executive vice president and chief commercial officer at Dexcom, discusses his company's new partnership with Fitbit and what patients with both type 1 and type 2 diabetes will get out of it.
Views: 755 AJMCtv
In this video, Richard Channick, MD, Director, Pulmonary Hypertension and Thromboendarterectomy Program, Massachusetts General Hospital, Boston, MA, speaks about the use of Macitentan for the treatment of pulmonary arterial hypertension (PAH). Dr Channick says that Macitentan, compared to placebo, significantly improved morbidity in PAH. The results demonstrated in the SERAPHIN clinical trial also proved that Macitentan decreased hospitalizations in patients with PAH. This video was taken on May 20, 2013, at the ATS 2013 International Conference in Philadelphia, PA.
Views: 1861 AJMCtv
Alan Balch, PhD, discusses the Institute for Clinical and Economic Review’s (ICER’s) Value Assessment Framework tool that aims to provide stakeholders in healthcare with evidence to make more informed decisions regarding new cancer therapies. Dr Balch also considers limitations to the tool’s effectiveness.
Views: 589 AJMCtv
Zachary Bloomgarden, MD; Robert Gabbay, MD, PhD, FACP; Silvio Inzucchi, MD; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, compare the results of recent trials that suggest the benefits of glucagon-like peptide-1 receptor agonists, for diabetes, in cardiovascular mortality.
Views: 488 AJMCtv
Zachary Bloomgarden, MD; Robert Gabbay, MD, PhD, FACP; Silvio Inzucchi, MD; Dennis P. Scanlon, PhD; and Kenneth Snow, MD, MBA, remark on forthcoming results of cardiovascular outcomes trials and discuss payer considerations for the newer treatment indications entering the market.
Views: 758 AJMCtv
Diabetes is an insidious cardiometabolic condition that continues to affect a growing population of young Americans, and is associated with high blood pressure, lipid abnormalities, and renal disease. The disease and its clinical sequelae are tightly interwoven with cardiovascular disease (CVD), acute coronary syndrome, and stroke. Consequently, there are substantial clinical implications for the optimal management of any underlying cardiometabolic disorder. While the topic of "metabolic syndrome" remains controversial and inconsistently defined, Dr Michael Weber emphasizes that glycosylated hemoglobin A1c (HbA1c), while the standard measure for the management of diabetes, is only one component of the overall picture - it is also essential to appropriately control body weight and size, blood pressure, and lipid levels.
Views: 128 AJMCtv
Gregory L. Fricchione, MD, Discusses How Mind and Body Medicine Assists in Chronic Disease Management
Views: 633 AJMCtv
The rivaroxaban plus aspirin combination therapy to treat patients with stable coronary or peripheral artery disease showed such benefits in the COMPASS trial that it should become the standard of care, said John Eikelboom, MBBS, MSc, FRCPC, associate professor at McMaster University.
Views: 418 AJMCtv
Farzad Mostashari, MD, co-founder and CEO of Aledade and former National Coordinator of Health Information Technology, discusses the benefits of Aledade’s technology, combined with its strategies and analytics, and how these tools are implemented among the practices with which Aledade is working.
Views: 405 AJMCtv
During this segment, Patrick F. Fogarty, MD, discusses the treatment goals for hemophilia, based on disease severity. Dr Fogarty defines prophylaxis, explains primary and secondary prophylaxis for the treatment of mild and severe hemophilia, and discusses the recommended target trough levels and dosage requirements based on disease severity. He continues by discussing how treatment expectations are similar between patients, their family members, and providers. From a pediatric standpoint, Dr Fogarty stresses the importance of providing patients the best opportunity for a normal lifestyle, and explains that as longer-acting proteins continue to develop, there is an opportunity to administer intravenous therapy less frequently. Dr Fogarty concludes by briefly discussing the benefits of the agents that are currently available to treat patients with mild and severe hemophilia, and cites a recent study that treated patients with a regimen of recombinant clotting factor 8 concentrate and revealed positive results on patients' quality of life.
Views: 326 AJMCtv
Amrita Krishnan, MD, FACP, elucidates various combination treatment approaches making use of daratumumab in the frontline setting for patients with newly diagnosed multiple myeloma.
Views: 374 AJMCtv
See more coverage from the AMCP Annual Meeting: http://www.ajmc.com/conferences/AMCPS2015 See more AJMCtv interviews with industry experts: http://www.ajmc.com/ajmc-tv/interviews
Views: 251 AJMCtv
The use of on-demand data in the healthcare setting has gone through an evolution, where the beginning steps were about pulling information into 1 pool and then understanding how to analyze it. According to Lidia Fonseca, senior vice president and chief information officer of Quest Diagnostics, the next step in this process is integrating this technology into the workflow of physicians and using the information in a real time and impactful way.
Views: 633 AJMCtv
New delivery models related to the recent healthcare reform legislation may help drive up utilization, as discussed by Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, in this seventh segment of the Healthcare Reform Stakeholders Summit, Spring 2015 series. They theorize that healthcare convenience and availability may actually lead to a loss in coordination of care.
Views: 1106 AJMCtv
In this segment, Mary Ann Hodorowicz, RDN, MBA, CDE, describes the combination therapies of insulin and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) as a “marriage made in heaven,” while Zachary Bloomgarden, MD, discusses the advantages of good glycemic control with less weight gain; an additional benefit is fewer gastrointestinal side effects, which often occurs with the GLP-1 RA therapies.
Views: 237 AJMCtv
Although nilotinib as a first-line therapy for chronic myelogenous leukemia is a more effective treatment than imatinib, nilotinib’s side effects are too much for patients, according to a study from Novartis presented at the 56th Annual Meeting of the American Society of Hematology. Giuseppe Saglio, MD, one of the co-authors on the study and a professor of internal medicine at the University of Turin in Italy, explained that while just 10% of patients who stopped imatinib did so because of side effects, 20% of patients on nilotinib stopped treatment because of side effects. “So I think, probably, we have to reconsider all this data to suggest which is the best appropriate treatment and particular dosage of the drug as first-line therapy,” Dr Salgio said.
Views: 419 AJMCtv
Simon Heller, MB, DM, discusses some of the consequences of hypoglycemia in diabetes management. Specifically, Heller points to the effect hypoglycemia can have on the cardiovascular system. "More recently it's become apparent that the hypoglycemia may have effects on other parts of the body, and the area of intense interest at the moment is the heart. We now know that hypoglycemia can produce changes within the cardiovascular system; it can increase the risk of thrombosis; it can set up inflammation; [and] it can cause abnormal cardiac repolarization," says Heller.
Views: 312 AJMCtv
The market for tardive dyskinesia, a movement disorder affecting 500,000 patients in the United States, will go from zero approved treatments to 2 in 2017, making it an important area to watch, said Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.
Views: 536 AJMCtv
Data analytics used to be done in a retrospective manner, and physicians would be looking at the data long after the patient left his or her visit. Now, Lidia Fonseca, senior vice president and chief information officer of Quest Diagnostics, explained that her and her team have brought data diagnostics back into the physician’s workflow for easier and faster use.
Views: 430 AJMCtv
Panel discussion moderated by Clifford Goodman, PhD, of The Lewin Group. Panelists were Andrea Baer, MS, of Mended Hearts, Inc; Jalpa A. Doshi, PhD, of University of Pennsylvania; Mary Richards of Partners for Better Care; Veena Shankaran, MD, MS, of University of Washington and Fred Hutchinson Cancer Research Center; and Kai Yeung, PharmD, PhD, of Group Health Research Institute. The discussion took place at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medication, which was co-hosted by the PAN Foundation and The American Journal of Managed Care.
Views: 3923 AJMCtv
Flatiron Health focuses on helping community oncologists because they still care for the majority of patients with cancer and make it possible for patients to get care without traveling long distances, explained Nat Turner, co-founder and CEO of Flatiron Health.
Views: 648 AJMCtv
John B. Buse, MD, PhD, reviews the findings from the ELIXA trial with lixisenatide in patients with type 2 diabetes.
Views: 369 AJMCtv
In this segment, Dennis P. Scanlon, PhD; Zachary T. Bloomgarden, MD, MACE; Robert Gabbay, MD, PhD, FACP; Michael Gardner, MD; and John A. Johnson, MD, MBA, consider the value of integrating the pharmacist into interdisciplinary care for patients with diabetes in various healthcare settings.
Views: 543 AJMCtv